As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: May 2, 2012
by The Press Association
A highly-toxic protein described as the “real bad guy” behind Alzheimer’s disease has been identified by scientists.
The molecule recruits other less harmful proteins and makes them deadly to brain cells, according to research published in the online edition of the journal Nature. Knowing how it forms and behaves is expected to lead to more effective Alzheimer’s treatments. One experimental drug to emerge from the research has already completed early phase I clinical trials.
The protein is a special type of beta-amyloid, which was already known to play a key role in Alzheimer’s. Beta-amyloid clumps together in the brains of Alzheimer’s patients, forming deposits that result in the destruction of nerve cells.
“This form of beta-amyloid, called pyroglutamylated (or pyroglu) beta-amyloid, is a real bad guy in Alzheimer’s disease,” said lead scientist Professor George Bloom, from the University of Virginia in the United States.
“We’ve confirmed that it converts more abundant beta-amyloids into a form that is up to 100 times more toxic, making this a very dangerous killer of brain cells and an attractive target for drug therapy.”
He compared the way the protein spread destruction in the brain to the transmission of prion diseases, such as Creutzfeldt Jakob Disease (CJD). Prion diseases are caused by rogue misshapen proteins that toxify other proteins they come into contact with in a chain reaction.
“You might think of this pyroglu beta-amyloid as a seed that can further contaminate something that’s already bad into something much worse – it’s the trigger,” said Prof Bloom.
Co-author Dr Hans-Ulrich Demuth, chief scientific officer at the German biotech company Probiodrug, said: “This publication further adds significant evidence to our hypothesis about the critical role pyroglu beta-amyloid plays in the initiation of Alzheimer’s disease.”
Probiodrug, based in Halle, has completed phase I safety trials of a drug that suppresses an enzyme involved in the formation of pyroglu beta-amyloid.
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
Foods can determine whether someone will suffer from dementia in later years, according to researchers at the Hebrew University of Jerusalem’s Faculty of Agriculture, Food and Environment in Rehovot. A large-scale international study that...
Taking care of someone with Alzheimer’s disease and other forms of dementia is not an easy task. Caregiving is a long-term endeavour that is mentally, emotionally, physically, and financially demanding, and is a role that...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.